Primary Ciliary Dyskinesia Market in the 7MM Projected for Significant Expansion from USD 101 Million| DelveInsight
DelveInsight’s latest “Primary Ciliary Dyskinesia Market Insight, Epidemiology and Market Forecast” report combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the market size for Primary Ciliary Dyskinesia (PCD) in 7MM, which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is expected to increase from approximately USD 101 million in 2023 over the next 10 years. Among the 7MM, the US market is expected to rise at a significant CAGR from approximately USD 36 million in 2023. This growth is attributed to increased awareness, improved screening and diagnosis rates, a rising prevalence of the disease, and the anticipated introduction of emerging therapies.
Download the Primary Ciliary Dyskinesia Market report to understand which factors are driving the primary ciliary dyskinesia therapeutic market @ Primary Ciliary Dyskinesia Market Trends.
The report also offers an in-depth epidemiological analysis and forecasts up to 2034, segmented by Primary Ciliary Dyskinesia prevalent cases, Primary Ciliary Dyskinesia diagnosed prevalent cases, age-specific cases, Primary Ciliary Dyskinesia prevalence by pathogenic variants in genes, and Primary Ciliary Dyskinesia prevalent cases by clinical manifestations across the 7MM. According to research conducted by DelveInsight’s analysts, the general prevalence of PCD is reported to be between 1 in 11,000 and 1 in 16,000 live births, although the actual prevalence may be higher. In the UK, the prevalence is estimated to be 1 in 7,500, with about 3,000 diagnosed prevalent cases. The US, on the other hand, has nearly 1,800 diagnosed prevalent cases in 2023 out of ~70,000 total diagnosed prevalent cases of PCD in 7MM. It has also been observed that children aged 6 to 20 years account for the highest number of cases, particularly in the United States, and this trend is expected to continue during the forecast period.
Discover evolving trends in the primary ciliary dyskinesia patient pool forecasts @ Primary Ciliary Dyskinesia Epidemiology Analysis.
DelveInsight’s analysis reveals that a decent number of companies are launching clinical trials to investigate new treatment options or improve existing ones. The clinical development pipeline includes drugs such as P-1037 IS/VX-371 (PARION SCIENCES), RCT1100 (RECODE THERAPEUTICS), ETH 42 (ETHRIS GmbH), CIL-05 (CILA THERAPEUTICS), among others.
As there is currently no standard treatment for PCD, the focus remains on managing respiratory symptoms, preventing infections, opening airways, and reducing inflammation through antibiotics, bronchodilators, or anti-inflammatory medications. This emphasises the potential of emerging diagnoses and therapies to revolutionise the treatment landscape for PCD.
Among the anticipated emerging therapies, RCT1100 by ReCode Therapeutics, an inhaled mRNA-based investigational therapy, shows promising results in restoring ciliary function in the lungs, addressing the root cause of PCD rather than merely controlling symptoms. The report provides a detailed analysis of the anticipated uptake rates for the potential PCD drugs expected to launch between 2025 and 2034.
Recent developments, including the US FDA’s Orphan Drug Designation (ODD) for RCT1100 by ReCode Therapeutics in June 2024, along with significant clinical trial updates for TH 42 (ETHRIS GmbH) and CIL-05 (CILA THERAPEUTICS), emphasise the momentum in the field.
Unlock which primary ciliary dyskinesia emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the Primary Ciliary Dyskinesia Drug Insights.
Although PCD presents significant challenges due to its frequent misidentification as a more common respiratory disorder, potentially leading to an underreporting of its true prevalence and significant delays in treatment, the emergence of improved diagnostic methods and novel therapies is set to broaden treatment options and spur market growth.
Table of Contents
|
1. |
KEY INSIGHTS |
|
2. |
REPORT INTRODUCTION |
|
3. |
PRIMARY CILIARY DYSKINESIA (PCD) MARKET OVERVIEW AT A GLANCE |
|
4. |
METHODOLOGY |
|
5. |
EXECUTIVE SUMMARY |
|
6. |
KEY EVENTS |
|
7. |
DISEASE BACKGROUND AND OVERVIEW |
|
8. |
PRIMARY CILIARY DYSKINESIA EPIDEMIOLOGY AND PATIENT POPULATION |
|
9. |
PRIMARY CILIARY DYSKINESIA PATIENT JOURNEY |
|
10. |
PRIMARY CILIARY DYSKINESIA EMERGING THERAPIES |
|
11. |
PRIMARY CILIARY DYSKINESIA MARKETED THERAPIES |
|
12. |
KOL VIEWS |
|
13. |
SWOT ANALYSIS |
|
14. |
PRIMARY CILIARY DYSKINESIA UNMET NEEDS |
|
15. |
MARKET ACCESS AND REIMBURSEMENT |
|
16. |
APPENDIX |
|
17. |
DELVEINSIGHT CAPABILITIES |
|
18. |
DISCLAIMER |
Related Reports:
Primary Ciliary Dyskinesia (PCD) Pipeline Insight
Primary Ciliary Dyskinesia (PCD) Pipeline Insight report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the PCD companies, including PARION SCIENCES, RECODE THERAPEUTICS, ETHRIS, and CILA THERAPEUTICS.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
